Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


I joined the Oxford neurology registrar rotation in 2020, and started my DPhil under the supervision of Dr AG Thompson and Professor MR Turner in 2022.

Training and qualifications

  • BSc 2013 Imperial College London
  • MBBS 2015 Imperial College London
  • MRCP 2018 Royal College of Physicians

David Lester

Clinical Research Fellow

DPhil key hypotheses

  • Clinical heterogeneity in amyotrophic lateral sclerosis (ALS) reflects differences in underlying disease biology
  • These differences in disease biology are reflected in the cerebrospinal fluid (CSF) proteome
  • Integrated analysis of the CSF proteome will allow separation of patients with ALS into distinct, biologically-relevant clusters linked to key aspects of clinical heterogeneity
  • Clusters can be used as a means to stratify patients to improve prediction of disease progression and, ultimately, response to more bespoke drug treatment